Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials

Erythropoietin in patients with AMI seems to have no clinical benefit for heart function or reducing infarct size, cardiovascular events, and all-cause mortality. Erythropoietin may not be a choice for patients with AMI.